AI assistant
Sending…
Marker Therapeutics, Inc. — Director's Dealing 2017
Sep 25, 2017
35150_dirs_2017-09-25_3475415e-08f7-4c36-914f-d162a7e4152c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: TAPIMMUNE INC. (TPIV)
CIK: 0001094038
Period of Report: 2017-09-22
Reporting Person: Hoang Peter L. (Director, CEO and President)
More from Marker Therapeutics, Inc.
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
Mar 20
Annual Report
2026
Mar 20
Proxy Solicitation & Information Statement
2026
Mar 20
Annual Report
2026
Mar 18
Regulatory Filings
2026
Feb 9
Director's Dealing
2025
Nov 19
Director's Dealing
2025
Nov 19
Director's Dealing
2025
Nov 19
Major Shareholding Notification
2025
Nov 17